These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 8403910)

  • 1. Pharmacokinetic study of RU 486 and its metabolites after oral administration of single doses to pregnant and non-pregnant women.
    Shi YE; Ye ZH; He CH; Zhang GQ; Xu JQ; Van Look PF; Fotherby K
    Contraception; 1993 Aug; 48(2):133-49. PubMed ID: 8403910
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetic study of orally administered RU 486 in non-pregnant women.
    He CH; Shi YE; Ye ZH; Zhang GG; Jiang NX; Van Look PF; Fotherby K
    Contraception; 1989 Oct; 40(4):449-60. PubMed ID: 2582770
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Pharmacokinetic study on RU 486 and its metabolites after oral administration of various doses in pregnant and non-pregnant women].
    Shi YE; Ye ZH; He CH; Zhang GQ
    Shengzhi Yu Biyun; 1992 Feb; 12(1):8-14. PubMed ID: 12344886
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inhibition of ovulation by low-dose mifepristone (RU 486).
    Ledger WL; Sweeting VM; Hillier H; Baird DT
    Hum Reprod; 1992 Aug; 7(7):945-50. PubMed ID: 1331167
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Plasma levels of antiprogestin RU 486 following oral administration to non-pregnant and early pregnant women.
    Swahn ML; Wang G; Aedo AR; Cekan SZ; Bygdeman M
    Contraception; 1986 Nov; 34(5):469-81. PubMed ID: 3816231
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Transplacental passage of mifepristone and its influence on maternal and fetal steroid concentrations in the second trimester of pregnancy.
    Hill NC; Selinger M; Ferguson J; MacKenzie IZ
    Hum Reprod; 1991 Mar; 6(3):458-62. PubMed ID: 1955558
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A randomized clinical trial of mifepristone (RU486) for induction of delayed menses: efficacy and acceptability.
    Grimes DA; Mishell DR; David HP
    Contraception; 1992 Jul; 46(1):1-10. PubMed ID: 1424618
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of mifepristone on dilatation of the pregnant and non-pregnant cervix.
    Gupta JK; Johnson N
    Lancet; 1990 May; 335(8700):1238-40. PubMed ID: 1971320
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pregnancy interruption with RU 486 in combination with dl-15-methyl-prostaglandin-F2 alpha-methyl ester: the Chinese experience.
    Gao J; Qiao GM; Wu YM; Wu ME; Zheng SR; Han ZB; Fan HM; Yao GZ; Meng U; Dubois C
    Contraception; 1988 Dec; 38(6):675-83. PubMed ID: 3219854
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dose and time dependent rise of plasma cortisol following administration of mifepristone in early pregnancy.
    Thong KJ; Brooks AN; Baird DT
    Br J Obstet Gynaecol; 1993 Sep; 100(9):880-2. PubMed ID: 8218022
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacokinetics of mifepristone after low oral doses.
    Kekkonen R; Heikinheimo O; Mandelin E; Lähteenmäki P
    Contraception; 1996 Oct; 54(4):229-34. PubMed ID: 8922876
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pretreatment with mifepristone (RU 486) reduces interval between prostaglandin administration and expulsion in second trimester abortion.
    Rodger MW; Baird DT
    Br J Obstet Gynaecol; 1990 Jan; 97(1):41-5. PubMed ID: 2407284
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Levels of the antiprogestin RU 486 and its metabolites in human blood and follicular fluid following oral administration of a single dose.
    Cekan S; Aedo AR; Segerstéen E; Van Look P; Messinis I; Templeton A
    Hum Reprod; 1989 Feb; 4(2):131-5. PubMed ID: 2918065
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Medical abortion in women of less than or equal to 56 days amenorrhoea: a comparison between gemeprost (a PGE1 analogue) alone and mifepristone and gemeprost.
    Norman JE; Thong KJ; Rodger MW; Baird DT
    Br J Obstet Gynaecol; 1992 Jul; 99(7):601-6. PubMed ID: 1525104
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [HPLC of RU 486 and its metabolites in human blood].
    Zhang GQ; Ye ZH; Shi YE; He CH; Bai XM; Xu JQ
    Shengzhi Yu Biyun; 1991 Feb; 11(1):26-31. PubMed ID: 12343816
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of Yuzpe regimen, danazol, and mifepristone (RU486) in oral postcoital contraception.
    Webb AM; Russell J; Elstein M
    BMJ; 1992 Oct; 305(6859):927-31. PubMed ID: 1458074
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The placental transfer of mifepristone (RU 486) during the second trimester and its influence upon maternal and fetal steroid concentrations.
    Hill NC; Selinger M; Ferguson J; MacKenzie IZ
    Br J Obstet Gynaecol; 1990 May; 97(5):406-11. PubMed ID: 2372525
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Early abortion induction by a combination of mifepristone and oral misoprostol: a comparison between two dose regimens of misoprostol and their effect on blood pressure.
    el-Refaey H; Templeton A
    Br J Obstet Gynaecol; 1994 Sep; 101(9):792-6. PubMed ID: 7947529
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacokinetics of the antiprogesterone RU 486 in women during multiple dose administration.
    Heikinheimo O
    J Steroid Biochem; 1989 Jan; 32(1A):21-5. PubMed ID: 2913396
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antiprogesterone steroid RU486. Pharmacokinetics and receptor binding in humans.
    Heikinheimo O
    Acta Obstet Gynecol Scand; 1990; 69(4):357-8. PubMed ID: 2244471
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.